Articles published by Telix Pharmaceuticals Limited
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
April 28, 2025
Telix Reports US$186M Q1 Revenue, Up 62% YOY
April 22, 2025
Telix Appoints Paul Schaffer as Chief Technology Officer
April 07, 2025
Anne Whitaker Appointed as Non-Executive Director
April 03, 2025
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
March 21, 2025
Telix Adds Lead-212 Isotope Production Capability
March 12, 2025
Illuccix® Approved in the United Kingdom
February 12, 2025
Telix Completes Acquisition of RLS (USA) Inc.
January 27, 2025
Illuccix® Receives European Approval
January 16, 2025
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
January 13, 2025
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
December 29, 2024
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
November 18, 2024
Telix ADSs Commence Trading on Nasdaq
November 13, 2024